Tolerability of paroxetine in Parkinson's disease: A prospective study

P. Martinelli, C. Scaglione, R. Lodi, S. Iotti, B. Barbiroli

Research output: Contribution to journalArticlepeer-review


Depression is a common finding in patients with Parkinson's disease (PD). Traditionally, depression has been treated with tricyclic antidepressants, which are often associated with undesirable side effects that may limit their use in PD. Few studies have been performed with selective serotonin reuptake inhibitors (SSRIs) in these patients. We assessed the tolerability of the SSRI antidepressant paroxetine (10-20 mg once per day) in 65 outpatients with PD and depression for a period of at least 3 months. Treatment was continued for 125.3 ± 89.6 days (mean ± standard deviation) in 52 patients. In these subjects the Hamilton Disease Rating Scale improved from 21.7 ± 6.4 to 13.8 ± 5.8 (p

Original languageEnglish
Pages (from-to)986-989
Number of pages4
JournalMovement Disorders
Issue number5
Publication statusPublished - 2000


  • Depression
  • Parkinson's disease
  • Paroxetine
  • Safety
  • SSRI
  • Tolerability

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)


Dive into the research topics of 'Tolerability of paroxetine in Parkinson's disease: A prospective study'. Together they form a unique fingerprint.

Cite this